Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05911880
Other study ID # 211247
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2021
Est. completion date December 15, 2024

Study information

Verified date August 2023
Source Instituto Nacional de Cardiologia Ignacio Chavez
Contact Fausto Sanchez, PhD
Phone 5555732911
Email fausto22@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The increase in autoimmune diseases in Western countries has been linked to environmental factors, and diet is considered a modifier of rheumatoid arthritis (RA). A high-fat diet promotes systemic inflammation and alters the microbiome. Certain bacteria in the intestinal microbiota generate proinflammatory metabolites from components of red meat, eggs, and dairy products. However, fruits and vegetables can modulate the gut microbiota and have been associated with reduced inflammation in RA patients. The aim of this study is to determine the changes in RA activity associated with plant-based dietary modifications. The study will evaluate men and women aged 18 years and older with low, moderate, or severe RA activity, and the intervention will involve an individualized, isocaloric plant-based diet for 14 days. The 28-joint disease activity score index and c-reactive protein (DAS 28-PCR) will be used to determine disease severity, in addition to analyzing the expression of inflammatory cytokines and microRNAs associated with RA.


Description:

The recent increase in autoimmune diseases in Western countries has seen environmental factors as important triggers of disease, as the genetic basis in affected populations has remained apparently constant. Diet has been seen as a modifying factor for several years in rheumatoid arthritis (RA). A high-fat diet alters the structure of the microbiome even in the absence of obesity. However, it is also an important factor that promotes excessive accumulation of white adipose tissue (WAT) and systemic inflammation. For several decades, it has been evaluated how the intestinal microbiome participates in the metabolism of some components of the diet and has the potential to modify the circulating proinflammatory or anti-inflammatory mediators. In the context of patients with RA, it has been found that the bacterium Prevotella Copri, found in greater proportion in patients with newly diagnosed rheumatoid arthritis, generates a pro-inflammatory metabolite called N-trimethylamine oxide derived from choline and carnitine present in red meat, eggs, and dairy products. On the other hand, fruits and vegetables can modulate the gut microbiota through dietary fiber. The proportion of anti-inflammatory bacteria Faecalibacterium Prausnitzii, is higher in vegetarian diets, which has been seen in fecal flora as beneficial in patients with RA associated with reduced inflammation. For several years, it has been reported in the literature that patients associate certain foods with increased or improved symptoms of the disease. However, a diet that combines several suggested strategies to reduce inflammation may represent a more significant intervention than just including specific foods in the diet. The role of the plant-based diet on RA activity has not been fully elucidated. Based on this background, the objective of this work will be to determine the decrease in RA activity associated with plant-based dietary modifications. To carry out this protocol, women and men aged 18 and over with low, moderate, or severe rheumatoid arthritis activity will be evaluated. For dietary intervention, at the beginning of treatment, patients will be evaluated anthropometrically (weight, height, body mass index, waist and hip circumference, waist-hip index, percentage of total fat, visceral fat, and percentage of muscle), and a basal blood sample will be taken at the end of the procedure. The kilocalories typically consumed will be calculated through a 24-hour reminder to set your personalized meal plan. A dietary table will be made with the following distribution of macronutrients: carbohydrates 57%, protein 18%, and lipids 25%. Subsequently, the food will be distributed in an equivalent distribution table, complying with the kilocalories and the percentage of macronutrients established. The consumption of food of animal origin will be reduced, replacing this protein with vegetable protein. The intervention will be carried out for 15 days, the menu will be modified at 7 days of intervention following the same specifications. At the end of the treatment, the patients will be evaluated under the same anthropometric conditions, and blood sampling for laboratory analyses. To determine the severity of the pathology, the DAS (Disease Activity Score) index will be used. A scale that measures RA activity. This scale influences the tumor and painful joint count on 28 joints, the rate of globular sedimentation (GSR), and the evaluation of the disease by the patient. This scale has a value of 0.0 to 9.4.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date December 15, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subjects over 18 years of age. - Established diagnosis of rheumatoid arthritis according to American College Rheumatoid (ACR) 1987 or ACR/European Alliance of Associations for Rheumatology (EULAR) 2010 criteria. - Disease activity according to DAS 28 (defined as all > 2.6). Exclusion Criteria: - Systemic autoimmune superposition syndrome (with the exception of: fibromyalgia, thyroid pathology, Type 1 Diabetes Mellitus, syndrome Sjögren and antiphospholipid syndrome) - Patients on treatment with coumarins - Patients with cancer, chronic hepatitis, HIV, pregnancy - Weight variations associated with diet in last 6 months

Study Design


Intervention

Behavioral:
Plant-based diet for 14 days in patients with rheumatoid arthritis.
Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.

Locations

Country Name City State
Mexico Instituto Nacional de Cardiología "Ignacio Chávez" Mexico City Tlalpan

Sponsors (1)

Lead Sponsor Collaborator
Instituto Nacional de Cardiologia Ignacio Chavez

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in disease activity by DAS28 at 14 days after with a plant-based diet Is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA).
The scores are divided as follows:
0-2.5: Remission 2.6-3.2: Low activity 3.3-5.1: Moderate activity >5.1: high activity This evaluates the joint count of 28 painful and inflamed joints in conjunction with the value of C-reactive protein (mg/L).
14 days
Secondary Change from baseline in C-Reactive Protein (CRP) by automated photometry at 14 days after with a plant-based diet RESULT SCALE:
< 5 mg/L = Low
= 5 mg/L = High
CRP (C-reactive protein) is a measure used to assess the presence and amount of inflammation in the body. The liver produces CRP, and its levels in the blood increase in response to acute or chronic inflammation. It is considered a non-specific marker of inflammation, meaning that its elevated levels can indicate various inflammatory conditions, such as infections, autoimmune diseases, chronic inflammatory disorders, and tissue damage.
CRP levels are evaluated by obtaining a fasting peripheral blood sample, with a minimum fasting period of 8 hours, using the venipuncture technique. The analysis is conducted using automated photometry.
14 days
Secondary Change from baseline in Erythrocyte Sedimentation Rate (ESR) by automated photometry at 14 days after with a plant-based diet RESULT SCALE:
2-26.00 mm/hr = Normal
= 26 mm/hr = High
Erythrocyte Sedimentation Rate (ESR) is a measure used to assess the presence of inflammation in the body. ESR is a non-specific indicator of inflammation and is based on the principle that red blood cells tend to clump together and settle more rapidly in the presence of inflammatory substances. It measures the distance that red blood cells descend in a test tube within one hour.
ESR levels are evaluated by obtaining a fasting peripheral blood sample, with a minimum fasting period of 8 hours, using the venipuncture technique. The analysis is conducted using automated photometry.
14 days
Secondary Change from baseline in glucose by automated photometry at 14 days after with a plant-based diet RESULT SCALE:
74-106 mg/dL = Normal
= 106 mg/dL = High
Measures blood glucose levels. Glucose is a type of sugar that is the main source of energy for the human body. Measuring glucose in a clinical chemistry study provides important information about glucose metabolism and blood sugar control.
Glucose levels are evaluated by obtaining a fasting peripheral blood sample, with a minimum fasting period of 8 hours, using the venipuncture technique. The analysis is conducted using automated photometry.
14 days
Secondary Change from baseline in Uric acid automated photometry at 14 days after with a plant-based diet RESULT SCALE:
2.40-5.70 mg/dL = Normal
= 5.71 mg/dL = High The parameter of uric acid in the blood is a measurement used in clinical chemistry to assess the levels of uric acid present in the body. Uric acid is a waste product generated by the breakdown of purines, which are substances found in certain foods and also occur naturally in the body.
Uric acid is transported through the bloodstream and is primarily eliminated through the kidneys in the form of urine. To evaluate uric acid levels, a fasting peripheral blood sample is obtained using the venipuncture technique, with a minimum fasting period of 8 hours. The analysis is conducted using automated photometry.
14 days
Secondary Change from baseline in total cholesterol concentration by automated photometry at 14 days after with a plant-based diet RESULT SCALE:
0-200 mg/dL = Normal
= 201 mg/dL = High
The parameter of total cholesterol in the blood is a measurement used in clinical chemistry studies to assess cholesterol levels in the body. Cholesterol is a lipid substance that is essential for the body's functioning, but elevated levels can increase the risk of cardiovascular diseases.
Total blood cholesterol includes both HDL (high-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol. Additionally, the measurement of total cholesterol may also include a fraction of triglycerides, which are another type of lipid.
To evaluate total cholesterol, a fasting peripheral blood sample is obtained using the venipuncture technique, with a minimum fasting period of 8 hours. The analysis is conducted using automated photometry.
14 days
Secondary Change from baseline in Atherogenic index at 14 days after with a plant-based diet RESULT SCALE:
1-4 = Normal
=5 = High The atherogenic index is a parameter used in blood chemistry analysis to assess the risk of cardiovascular disease. This index provides information about the ratio between LDL (low-density lipoprotein) cholesterol and HDL (high-density lipoprotein) cholesterol in the blood.
The index is calculated by dividing the LDL cholesterol by the HDL cholesterol. A high atherogenic index indicates an elevated ratio of LDL cholesterol to HDL cholesterol, which may indicate an increased risk of cardiovascular disease. Conversely, a lower index falls within the normal range and suggests a healthier cardiovascular profile.
14 days
Secondary Change from baseline in body weight by bioelectric impedance analysis at 14 days after with a plant-based diet RESULT SCALE:
Kilograms The body weight is measured using bioimpedance; a technique employed to assess body weight and gather additional information about an individual's body composition. During a bioimpedance measurement, a low-intensity electrical current is passed through the body, and the resistance encountered by body tissues is measured.
Bioimpedance measurement of body weight is based on the principle that electrical current flows more easily through tissues with higher water content, such as muscles, while encountering greater resistance in tissues with lower water content, such as body fat.
14 days
Secondary Change from baseline in waist-to-hip index by bioelectric impedance analysis at 14 days after with a plant-based diet Result scale:
Female <0.80 = Low 0.81-0.85 = Moderate 0.86 = High
Male:
<0.95 = Low 0.96-1 = Moderate
1 = High
The waist-to-hip ratio is a measurement used to assess body fat distribution. To calculate the waist-to-hip ratio, you divide the waist circumference by the hip circumference.
The waist-to-hip ratio serves as a general indicator of body fat distribution.
14 days
Secondary Change from baseline in body mass Index (BMI) by bioelectric impedance analysis at 14 days after with a plant-based diet Result scale:
Underweight: BMI < 18.5 kg/m2 Normal weight: BMI 18.5 - 24.9 kg/m2 Overweight: BMI 25 - 29.9 kg/m2 Class I obesity: BMI 30 - 34.9 kg/m2 Class II obesity: BMI 35 - 39.9 kg/m2 Class III obesity (morbid obesity): BMI = 40 kg/m2
The body mass index (BMI) is a measurement used to assess whether a person has a healthy weight in relation to their height. It is calculated by dividing a person's weight in kilograms by the square of their height in meters (BMI = weight / height²).
BMI provides a general estimate of a person's amount of body fat and is used to assess the risk of developing certain weight-related diseases, such as obesity and heart disease.
14 days
Secondary Change from baseline in body fat percentage by bioelectric impedance analysis at 14 days after with a plant-based diet Result scale:
Sex Age Low Normal High Very High Female 20-39 < 21.0 21.0 - 32.9 33.0 - 38.9 >39 Female 40-59 < 23.0 23.0 - 33.9 34.0 - 39.9 >40 Female 60-79 < 24.0 24.0 - 35.9 36.0 - 41.9 >42 Male 20-39 < 8.0 8.0 - 19.9 20.0 - 24.9 >25 Male 40-59 < 11.0 11.0 - 21.9 22.0 - 27.9 >28 Male 60-79 < 13.0 13.0 - 24.9 25.0 - 29.9 >30 The body fat percentage is a measurement that indicates the proportion of fat in relation to the total weight of a person's body. It is a significant measure for assessing body composition.
It is calculated using bioimpedance.
14 days
Secondary Change from baseline in visceral fat by bioelectric impedance analysis at 14 days after with a plant-based diet Result scale:
5-9 kilograms = Normal 10-14 kilograms = High
15 kilograms = Very high
This measurement assesses the amount of specific body fat that accumulates in the abdomen and surrounding vital organs. It is obtained through bioimpedance.
14 days
Secondary Change from baseline in skeletal muscle percentage by bioelectric impedance analysis at 14 days after with a plant-based diet The skeletal muscle percentage is a measurement that reflects the proportion of skeletal muscle in relation to the total body weight of an individual. It is a significant indicator used to evaluate body composition.
Result scale:
Sex Age Low Normal High Very high Female 18-39 < 24.3 24.3 - 30.3 30.4 - 35.3 >35.4 Female 40-59 < 24.1 24.1 - 30.1 30.2 - 35.1 >35.2 Female 60-80 < 23.9 23.9 - 29.9 30.0 - 34.9 >35 Male 18-39 < 33.3 33.3 - 39.3 39.4 - 44.0 >44.1 Male 40-59 < 33.1 33.1 - 39.1 39.2 - 43.8 >43.9 Male 60-80 < 32.9 32.9 - 38.9 39.0 - 43.6 >43.7 This measurement is calculated using bioimpedance technique.
14 days
Secondary Change from baseline in metabolic age by bioelectric impedance analysis at 14 days after with a plant-based diet Result scale:
Measured in years. Body age is determined based on your basal metabolism. It takes into account factors such as weight, body fat percentage, and skeletal muscle percentage to calculate a reference value. This value helps determine whether your body age is higher or lower than your actual age.
14 days
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4